(2S,3S,4S,5R,6S)-6-[4-[(5S,5aR,8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 木脂素内酯
• 英文名称: (2S,3S,4S,5R,6S)-6-[4-[(5S,5aR,8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
• 化学式: C₃₅H₄₀O₁₉
• 分子量: 764.7
• InChiKey: URCVASXWNJQAEH-KAYSAPKKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  54
• 可旋转键数：
  8
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  257
• 氢给体数：
  6
• 氢受体数：
  19

文献信息

• [EN] BIOMARKERS OF REDUCED INSULIN ACTION<br/>[FR] MARQUEURS BIOLOGIQUES D'UNE ACTION RÉDUITE DE L'INSULINE
  申请人：MAYO FOUNDATION

  公开号：WO2012058298A1

  公开（公告）日：2012-05-03

  This document provides methods and materials for assessing metabolic disorders related to reduced insulin action (e.g. insulin resistance or insulin deficiency) in a mammal (e.g. human). For example, methods and materials for assessing insulin resistance, risk of developing insulin resistance and monitoring efficacy of insulin resistance treatment are provided.